News coverage about Derma Sciences (NASDAQ:DSCI) has trended positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Derma Sciences earned a news impact score of 0.31 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 43.6568126847622 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Derma Sciences (NASDAQ DSCI) remained flat at $$7.00 during trading on Wednesday. The stock had a trading volume of 57,400 shares, compared to its average volume of 719,592. Derma Sciences has a 12-month low of $2.92 and a 12-month high of $7.05.

COPYRIGHT VIOLATION WARNING: “Derma Sciences (DSCI) Earns Daily News Impact Score of 0.31” was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with's FREE daily email newsletter.